Dicerna Pharma (DRNA) Misses Q2 EPS by 94c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500, Nasdaq set for higher open as oil prices extend declines, midterm results awaited
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts DRNA Hot Sheet
Join SI Premium – FREE
Dicerna Pharma (NASDAQ: DRNA) reported Q2 EPS of ($0.53), $0.94 worse than the analyst estimate of $0.41. Revenue for the quarter came in at $41.3 million versus the consensus estimate of $91.29 million.
For earnings history and earnings-related data on Dicerna Pharma (DRNA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Apple’s ’unprecedented’ memory warning adds fuel to wobbly Micron, SK hynix trade
- Expeditors Int'l (EXPD) Tops Q3 EPS by 45c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
